Fig. 5: The loss of RASSF10 expression correlates with clinical diagnosis and prognosis of human neoplasia of the kidney. | Oncogene

Fig. 5: The loss of RASSF10 expression correlates with clinical diagnosis and prognosis of human neoplasia of the kidney.

From: RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice

Fig. 5

a RASSF10 expression is decreased in various kidney cancer types (log2, data Kort, Anova one way) and RASSF10 downregulation was verified in b chromophobe, papillary and clear cell renal carcinoma (log2, data TCGA, Wilcoxon). c The loss of RASSF10 expression correlated with kidney tumor stage in chromophobe cell carcinoma (log2, data TCGA, Anova one way) and d in clear cell carcinoma (data TCGA, Anova one way). e In renal papillary cell carcinoma and f renal clear cell carcinoma low RASSF10 levels correlated with reduced 5-year overall survival (data Pan-Cancer RNAseq). High RASSF10 methylation levels correlated with reduced survival in g renal papillary and h clear cell carcinoma (data TCGA). i RASSF10 levels are reduced with increasing cyst size in polycystic kidney disease (ADPKD, small cysts: <1 ml with n = 5 and each pool of 4; medium cysts: 10–25 ml with n = 5; large cysts > 50 ml with n = 3), (log2, data Pei, Anova one way).

Back to article page